Frailty in Patients With Cirrhosis
Purpose of review
This review gives an overview of the evolving concept of physical frailty in patients with cirrhosis. As well as summarizing the available metrics that have been used to diagnose it, this review also examines the major recent trials that have investigated frailty in patients with cirrhosis. The complex relationship between sarcopenia and frailty is explored, and strategies to optimize frailty, such as including pharmacological and non-pharmacological therapies, are discussed.
Though there is heterogeneity between studies on how physical frailty in cirrhosis has been assessed, it is nonetheless becoming increasingly apparent that frailty in cirrhosis contributes to poor outcomes. A growing body of evidence strongly supports that frailty, as an entity distinct from comorbidity or measurable by laboratory-based liver disease severity, contributes to pre-transplant mortality and unplanned hospital admissions. If taken into account, frailty may improve pre-transplant mortality risk prediction.
Physical frailty in cirrhosis may be objectively assessed by a number of validated metrics though at present, we lack a uniform consensus on the most appropriate tool. Early identification of frailty may allow optimization of the patient with the potential to avoiding adverse outcomes. Further studies are awaited validating and exploring optimal approaches to diagnosing and reversing frailty.
KeywordsFrailty Cirrhosis Sarcopenia
Branched-chain amino acids
Clinical Frailty Scale
Fried Frailty Criteria
Model for end-stage liver disease
Short Physical Performance Battery
6-min walking distance
BK: Drafted the final manuscript.
PT: Revision of the final manuscript.
Compliance with Ethical Standards
Conflict of Interest
Beverley Kok declares that she has no conflict of interest.
Puneeta Tandon declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.•• Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14(8):1870–9. Landmark study introducing the concept of frailty and its negative impact on outcomes in patients with cirrhosis.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.• Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the Clinical Frailty Scale. Am J Gastroenterol. 2016;111(12):1759–67. Study supporting the use of a “clinic-friendly” global frailty scale to rapidly screen patients and identify whether they were at high risk of unplanned hospitalization or death.CrossRefPubMedGoogle Scholar
- 6.• Dunn MA, Josbeno DA, Tevar AD, Rachakonda V, Ganesh SR, Schmotzer AR, et al. Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization. Am J Gastroenterol. 2016;111(12):1768–75. Study supporting the use of a single component assessment—gait speed—as a marker of hospitalization in patients with cirrhosis. Relevant discussion about the cost implications of frailty.CrossRefPubMedGoogle Scholar
- 7.•• Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66(2):564–74. This study provides clinicians with a prospectively established battery of 3 tools—the “liver frailty index” for the prediction of waitlist mortality.CrossRefPubMedGoogle Scholar
- 9.• Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16(12):1373–8. A seminal study which highlighted the impact of muscle function on outcomes in patients with cirrhosis.CrossRefPubMedGoogle Scholar
- 14.Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.CrossRefPubMedGoogle Scholar
- 16.ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.Google Scholar
- 30.van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, Systematic Review JNIJ. Meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2016;16(8):2277–92.CrossRefGoogle Scholar
- 40.Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev. 2012;(5):Cd008344. https://doi.org/10.1002/14651858.CD008344
- 44.• Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557–66. Key study illuminating the beneficial effect on lean body mass in patients with cirrhosis by avoiding prolonged overnight fasting.CrossRefPubMedGoogle Scholar
- 45.Duarte-Rojo A, Ruiz-Margain A, Montano-Loza AJ, Macias-Rodriguez RU, Ferrando A, Kim WR. Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl. 2018;24(1):122–39.CrossRefPubMedGoogle Scholar